CD274 and hepatocellular carcinoma: A retrospective study investigated the clinical outcomes and safety of PD-1/PD-L1 inhibitors combined with palliative radiotherapy and anti-angiogenic therapy in advanced Barcelona clinic liver cancer (BCLC) stage C hepatocellular carcinoma [53].